Physician profile
Ryan Gotcher
NPI 1740621291
$13,738.38
in general payments reported to CMS, 2019-2025
53 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,487 · 2020: $1,723 · 2021: $2,140 · 2022: $1,995 · 2023: $1,973 · 2024: $1,691 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,394.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,118.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,370.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,370.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,070.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,017.02 | 2020-2025 | |
| Pfizer INC. | $927.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $901.17 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $570.41 | 2019-2025 | Prolia, Evenity, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $552.26 | 2020-2024 | Trintellix |
| Abbott Laboratories | $482.67 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.67 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $293.70 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $267.43 | 2019-2022 | |
| Astellas Pharma US INC | $267.32 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $236.65 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gotcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.